Original news and analysis on international IP policy
In this week's highly anticipated visit to the United States by Indian Prime Minister Narendra Modi, a number of joint statements have been issued, raising hope for greater cooperation between the two countries, and some concern about the same.
Health Action International Europe, and Oxfam today issued a briefing paper entitled, “Trading Away Access to Medicines: How the European trade agenda continues to undermine access to medicines.” The paper argues that new concerns such as the ebola virus and the threat of unchecked antimicrobial resistance show the need for a new model for financing pharmaceutical research and development.
The World Health Organization has published an analysis of the patent situation for new hepatitis treatments, and a call for possible pharmaceutical products for prequalification.
French Minister for Social Affairs, Health and Rights of Women Marisol Touraine today announced a national programme to reduce tobacco use in France, including plain packaging.
A side event to this week’s World Intellectual Property Organization annual General Assembly highlighted the work of the Geneva-based Medicines Patent Pool in fighting HIV/AIDS, and discussed whether it makes sense for the patent pool model to be extended to other diseases.
Gilead on 15 September struck voluntary licence deals with seven India-based generic manufacturers to expand access to its hepatitis C innovative drugs in developing countries. With a limited territory covered, this, yet deserving, pact raises doubts about the coherence of Indian counterparts at a time when there are no relevant patents in India, several pre-grant oppositions have been filed and unrestrained competition by compulsory licences could have been pursued, writes Daniele Dionisio.
A number of side events have been scheduled during the annual General Assemblies of the World Intellectual Property Organization this week. The range of events are organised by WIPO as well as governmental and non-governmental organisations working in areas such as public health, finance, copyright, geographical indications and innovation.
IRVINE, CALIFORNIA – Experts gathered here last week addressed the question of – one year later - what does the United States Supreme Court’s decision on human gene patents mean for scientific research and patent policy?
What is a mandatory licence? Mandatory licenses are a legal remedy within the intellectual property flexibilities provided by the World Trade Organization allowing a government to grant permission to third parties to produce a patented product or use a patented process without the consent of the patentee, in order to address a priority status for the country.
Applicants to the European “Innovation Communities” initiative have until 10 September to submit joint innovation proposals in the areas of healthy aging and raw materials. The aim is to create new organisations compliant with the European grant programme Horizon 2020, which will operate under flexible intellectual property rights’ policies in collaborative innovation projects.
The world and the global health community have been taken by surprise by the worst outbreak of Ebola so far. The World Health Organization today (5 September) said a vaccine could be available in November 2014 if proven safe. So far, according to the WHO, intellectual property issues have not acted as a barrier to accessing potential treatments and vaccines, and the focus for now is on emergency measures to find health solutions.
Will India’s new government bring in radical changes in the country’s intellectual property rights regime? That question has generated enormous buzz but no definitive answer ever since the Bharatiya Janata Party (BJP) swept to power with a decisive mandate in May this year.
[Update: the Indian government has announced that it has begun a process for a comprehensive IPR policy over the next six months, including a government think tank. See report here. The government website is here.]